• Thurs news: Novartis buys Kate Therapeutics. Trump’s likely FDA pick. Bayer tries for new Nubeqa indications. New CSO for Amgen. Versant developing new type of obesity drug. See more on our front page

Karyopharm - oncology

Quote




















Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S - Simply Wall St News

https://simplywall.st/stocks/us/pha...dnt-be-surprised-by-karyopharm-therapeuti/amp


“As expected, our analysis of Karyopharm Therapeutics' analyst forecasts confirms that the company's underwhelming revenue outlook is a major contributor to its low P/S. Shareholders' pessimism on the revenue prospects for the company seems to be the main contributor to the depressed P/S. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.”
 












































My issue is our leadership, RBD's and up, are not realistic at all. Stop with all the busy work, and daily pressure for more bottles and your fake enthusiasm, pretending this is a good company or a good drug It is neither, and your cheerleading is nauseating.

Just be honest, say this is a really tough drug to sell and a hard company to stick with based on all the setbacks. Thank you for sticking it out, as well know we have lost many good people who didn't want to see it through.

Just say, 'I will leave you alone, I am here if you need me, that there will be no more time wasting business reviews, or panicked calls on Friday when the bottle count is low. We understand that the MM market is well established and there will be little change to our share/volume, despite all of the "activity" we ask you to do'. That is what good leaders who get it say to their teams...not the daily 'lies' ours say to us.

The only things that will save us is a buyout(unlikely until data reads out) or highly differentiated clinical data which we know if further away than we were once told. Until then just give it a rest. We'll go out and make our calls, and do our admin, but let's please stop with all the meetings, Zooms, field visits, executive visits and all the other 'optics' that do nothing...they are all a waste of time and money do not move the needle at all.
 












anonymous said:
My issue is our leadership, RBD's and up, are not realistic at all. Stop with all the busy work, and daily pressure for more bottles and your fake enthusiasm, pretending this is a good company or a good drug It is neither, and your cheerleading is nauseating.

Just be honest, say this is a really tough drug to sell and a hard company to stick with based on all the setbacks. Thank you for sticking it out, as well know we have lost many good people who didn't want to see it through.

Just say, 'I will leave you alone, I am here if you need me, that there will be no more time wasting business reviews, or panicked calls on Friday when the bottle count is low. We understand that the MM market is well established and there will be little change to our share/volume, despite all of the "activity" we ask you to do'. That is what good leaders who get it say to their teams...not the daily 'lies' ours say to us.

The only things that will save us is a buyout(unlikely until data reads out) or highly differentiated clinical data which we know if further away than we were once told. Until then just give it a rest. We'll go out and make our calls, and do our admin, but let's please stop with all the meetings, Zooms, field visits, executive visits and all the other 'optics' that do nothing...they are all a waste of time and money do not move the needle at all.
Click to expand...
I asked R P for comment but he was too busy getting a bikini wax.
 




Top Bottom
Back
Quote